| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907) |
| Indication |
For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent. |
| Pharmacology |
Sulfasalazine is an anti-inflammatory indicated for the treatment of ulcerative colitis and rheumatoid arthritis. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Half Life |
5-10 hours |
| Elimination |
The majority of 5-ASA stays within the colonic lumen and is excreted as 5-ASA and acetyl-5-ASA with the feces. |
| Distribution |
* 7.5 ± 1.6 L |
| Clearance |
* 1 L/h [IV administration] |
| External Links |
|